Effects of Lubiprostone, an Intestinal Secretagogue, on Electrolyte Homeostasis in Chronic Idiopathic and Opioid-induced Constipation.

Goals: To assess short-term and long-term effects of lubiprostone, a type-2 chloride channel activator, on electrolyte homeostasis.

Background: Conventional laxatives are associated with electrolyte imbalances. Lubiprostone is a type-2 chloride channel activator approved for treating chronic idiopathic constipation (CIC), opioid-induced constipation (OIC), and constipation-predominant irritable bowel syndrome in women.

New insights into the structure of membrane fouling by biomolecules using comparison with isotherms and ATR-FTIR local quantification.

The objective of this paper was to propose a deepened analyze of a microfiltration membrane fouling by two biomolecules: a protein (Bovine Serum Albumin) and a peptide (Glutathione). In addition to an analysis of flux decline, the mass of biomolecules accumulated on the membrane during filtration was quantified and compared to adsorption experiments, using Fourier Transform Infra Red spectroscopy in Attenuated Total Reflection mode (ATR-FTIR). It was demonstrated that the same quantity of accumulated biomolecules on the apparent membrane area can generate totally different flux declines because of different fouling mechanisms.

Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders.

Background: Lubiprostone is a ClC-2 chloride channel activator approved for the treatment of chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC) in adults and irritable bowel syndrome with constipation (IBS-C) in women. Lubiprostone is generally well tolerated, with nausea being the most common adverse event.

Aims: To characterize nausea with lubiprostone using pooled results from clinical studies in patients with CIC, OIC, or IBS-C.

Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel.

Dapivirine, a nonnucleoside reverse transcriptase inhibitor, is in development as a microbicide for the protection of women against HIV infection. A randomized, double-blind, phase 1 trial was conducted in 36 healthy HIV-negative women to compare the pharmacokinetics of 2 dapivirine vaginal gel formulations (0.05% each) and their safety with the hydroxyethyl cellulose-based universal placebo gel.